Dr. Richter on Toxicities of Treatments for Multiple Myeloma

Joshua Richter, MD
Published: Wednesday, Feb 28, 2018



Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

According to Richter, toxicities are becoming more of an issue in multiple myeloma. Physicians need to understand where the difficulty comes from. There are many new drugs, and these drugs may offer many patients tremendous outcomes; however, there is also a significant amount of financial burden for the patient and their family.

Patients often plunge themselves into deep financial troubles in order to support the care for their own disease, which may affect their family, explains Richter. As a physician, it is important to be concerned about the system as a whole, but it is also important to understand the effects of financial burden on each individual patient, adds Richter.

SELECTED
LANGUAGE


Joshua Richter, MD, a hematologist/oncologist specializing in multiple myeloma at the John Theurer Cancer Center, discusses toxicities in the treatment of patients with multiple myeloma.

According to Richter, toxicities are becoming more of an issue in multiple myeloma. Physicians need to understand where the difficulty comes from. There are many new drugs, and these drugs may offer many patients tremendous outcomes; however, there is also a significant amount of financial burden for the patient and their family.

Patients often plunge themselves into deep financial troubles in order to support the care for their own disease, which may affect their family, explains Richter. As a physician, it is important to be concerned about the system as a whole, but it is also important to understand the effects of financial burden on each individual patient, adds Richter.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x